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Abstract—Cancer survival prediction is an active area of re-
search that can help prevent unnecessary therapies and improve
patient’s quality of life. Gene expression profiling is being widely
used in cancer studies to discover informative biomarkers that
aid predict different clinical endpoint prediction. We use multiple
modalities of data derived from RNA deep-sequencing (RNA-
seq) to predict survival of cancer patients. Despite the wealth
of information available in expression profiles of cancer tumors,
fulfilling the aforementioned objective remains a big challenge,
for the most part, due to the paucity of data samples compared to
the high dimension of the expression profiles. As such, analysis of
transcriptomic data modalities calls for state-of-the-art big-data
analytics techniques that can maximally use all the available data
to discover the relevant information hidden within a significant
amount of noise. In this paper, we propose a pipeline that
predicts cancer patients’ survival by exploiting the structure of
the input (manifold learning) and by leveraging the unlabeled
samples using Laplacian support vector machines, a graph-based
semi supervised learning (GSSL) paradigm. We show that under
certain circumstances, no single modality per se will result in
the best accuracy and by fusing different models together via
a stacked generalization strategy, we may boost the accuracy
synergistically. We apply our approach to two cancer datasets and
present promising results. We maintain that a similar pipeline can
be used for predictive tasks where labeled samples are expensive
to acquire.
I. INTRODUCTION
Cancer survival prediction provides valuable information
for oncologists to choose an effective course of treatment for
cancer patients. This is particularly important for terminally
ill patients for whom uninformed treatment selection can
undermine patients’ quality of life [9]. Unfortunately, there
is a high amount of stochasticity involved in regard to this
clinical endpoint due to numerous confounding factors (e.g.,
environmental factors) that can play a role in patients’ survival.
As a result, physicians often make subjective decisions based
on their past experience. Yet another major challenge when
dealing with clinical and omics data pertaining to the cancer
patients is that a significant portion of these data are unlabeled
due to the lack of adequate follow-up information. This is
especially the case for the longitudinal studies that span
several years (often more than five years,) which results in
patient withdrawal from the study or are subject to research
budget restrictions. As a result, most research studies filter out
these samples and solve the problem within the framework of
supervised learning. Even though this strategy works for larger
datasets, it fails to produce accurate and robust results in most
cancer datasets where small sample sizes remain a bottleneck.
This, along with the high dimensionality of the input data,
makes the objective difficult to achieve. An alternative to the
above-mentioned strategy would be to leverage the information
present in the available unlabeled data which are sometimes
orders of magnitude bigger in size, compared to the amount
of labeled samples. This approach falls into the category of
the semi-supervised learning paradigm.
Semi-supervised learning (SSL) is a learning paradigm that
takes advantage of both labeled and unlabeled data when
training a model. Traditionally, models trained for predictive
tasks are either supervised or unsupervised. While the labeled
data convey valuable information that can be leveraged to train
a model, they are not always available in abundance. On the
other hand, the unlabeled data may be readily available in large
quantities as they may be cheaper or faster to generate. In the
case of cancer data, for example, it is often costly to conduct a
long-term research study where the patient eventually dies due
to his/her disease. Consequently, the outcome corresponding
to the endpoint of study may not be known for a significant
part of the dataset. Even though the unlabeled data do not
tell us as much about the prediction outcome, may provide
some information about the distribution of data that can be
exploited to guide model training and lead us to a higher
predictive power. However, the key requirement for any SSL
method to succeed is that the marginal data distribution has to
carry some useful information regarding the inference of the
posterior probability [4] (the Bayes rule.)
To date, several SSL classification paradigms have been
proposed (such as self-training, co-training, transductive SVM
[TSVM] and graph-based semi-supervised learning [GSSL]).
Despite the success of SSL in different domains, their appli-
cation to the prediction of clinical endpoints is relatively new.
Here, we give an account of the related published studies in
chronological order.
As one of the earliest applications of GSSL to tumor
classification, Gui et al. [10] used a graph-based approach
named local and global consistency (LGC) [27]. LGC is an
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iterative algorithm inspired from the spreading of activation
networks from experimental psychology that can be explained
as random walks on graphs. The main idea in LGC is that each
unlabeled sample receives some amount of information from
its neighbors, which is retained according to some learning
rate. In the end, based on the amount of information each
unlabeled node receives from other nodes, the label of that
node is specified. Note that, one key difference between
Laplacian SVM and LGC is that the latter is not considered
to be a large margin classifier. Therefore, caution should
be practiced when generalization is a concern. Shi et al.
[24] used transductive support vector machines (TSVM) to
predict recurrence in colorectal cancer patients using mi-
croarray gene expression data. TSVM decides the labels for
unlabeled samples such that the classification boundary can
be placed in a low density region with the margin maximized.
This approach, however, is not an appropriate choice when
there is no clear boundary between the samples of different
classes, which is often the case for cancer data. A similar
approach [19] for prediction of cancer subtypes has also been
reported. In another successful application of GSSL, Kim et
al. [16] used manifold regularization to enforce smoothness
constraints on the intrinsic geometry of the marginal input
distribution. They applied their developed method to predict
different clinical endpoints such as survival. Moreover, they
used different modalities of genomic data and represented each
with a graph Laplacian and showed that, by generating a graph
Laplacian as a weighted sum of each individual Laplacian, the
solution follows the same analytic form. However, due to the
quadratic form of the cost function, it could be considered
more of a semi-supervised extension to the regularized least
squares method and lacks margin generalization. They used
a similar approach in their follow-up studies [15], [14]. In
another GSSL-related study, Kim et al. [17] used two levels of
semi-supervised learning to integrate different layers of omics
data. Iteratively, they trained separate GSSL methods on each
omics dataset, then used co-training to assign pseudo-labels to
the unlabeled samples. More recent published research using
similar techniques can be found in [8], [12], [3], [6], [22].
In this article, we develop a pipeline for prediction of cancer
survival based on Laplacian support vector machines, an ex-
tension of support vector machines to the semi-supervised do-
main. This method incorporates the geometry of the marginal
input distribution and maintains a balance between the loss
function and semi-supervised smoothness assumptions where
intuitively smoothness means data samples that are closer to
each other in the input space, should also be closer in terms
of the labels they are assigned. Moreover, we compare and
contrast the efficacy of the proposed method as a function of
the size of the labeled and unlabeled sets.
II. MANIFOLD REGULARIZATION & LAPLACIAN SVM
Semi-supervised learning differs from supervised learning
in that the underlying dataset consists of a set of l labeled
inputs (xi, yi)li=1 and a set of u unlabeled samples (xi)
l+u
i=l+1.
As such, there is a probability distribution P on X ×R from
which examples are drawn. On the other hand, assuming that
the unlabeled samples are drawn from the same underlying
stochastic process, they should be distributed according to the
marginal distribution PX of the original P . Graph-based semi-
supervised learning (GSSL) [27], on the other hand, is based
on the assumption that if the data lie on a manifold of much
lower dimensions (the intrinsic geometry of PX ) than that
of the input space, then by enforcing smoothness constraints
on that manifold for both labeled and unlabeled samples, we
can produce a classifier that is more consistent with the input
data [5]. GSSL represents each data sample as a node in a
weighted graph where the weight attributed to each edge, wij ,
is computed according to an affinity function, defined shortly.
This results in a dense graph which is often not desired and
hence, in a later step, sparsified using techniques such as k-
nearest neighbor. The resulting graph serves as a proxy for
the manifold and is used within the framework of a variety of
manifold regularization techniques. One important matrix that
is defined over this graph and which plays an important role
in derivation of many of the GSSL based approaches is the
graph Laplacian, computed as L =W−D where W = [wij ]i,j
is the affinity matrix and the diagonal matrix D is given by
Dii =
∑l+u
j=1 wij .
Proposed by Belkin et al. [2], manifold regularization is
a family of semi-supervised learning algorithms that exploits
the intrinsic geometry of the marginal distribution PX by
adding an additional regularization term. The support of PX
is assumed to have the geometric structure of a Riemannian
manifold M [1]. Within this framework, one can derive an
extension to the support vector machine by using the soft
margin loss function and thereby incorporating the manifold
structure of the input. As a result, the extended classifier not
only leverages the manifold structure of the input but also
remains a large margin classifier with useful generalization
implications that make it an effective tool when dealing with
data scarcity. Formally speaking, for any given Mercer kernel
[23], K : X × X → R, and the corresponding norm, ‖ ‖K ,
a number of popular algorithms including SVM can be cast
into the following minimization form with different empirical
cost functions:
f∗ = arg min
f∈HK
1
l
l∑
i=1
V (xi, yi, f) + γ‖f‖2H (1)
where V is some loss function and HK is the reproducing ker-
nel Hilbert space (RKHS) of functions X → R corresponding
to kernel K. The regularization term in equation 1 imposes
smoothness conditions on possible solutions. According to the
represented theorem the solution to equation 1 exists in HK
and can be expressed as,
f∗(x) =
l∑
i=1
αiK(xi, x) (2)
and, as a result, the problem reduces to optimizing over
the finite dimensional space of coefficient αi. The problem
with this framework, however, is that it only enforces the
smoothness constraint in the kernel space (aka the ambient
space) but does not take into account the smoothness of the
solution over the manifold, that is, the geometric structure
of PX . To achieve this, they add an extra regularizer to
enforce the smoothness of the solution relative to the manifold
which expands the minimization problem in equation 1, to the
following:
f∗ = arg min
f∈HK
1
l
l∑
i=1
V (xi, yi, f) + γA‖f‖2H + γI‖f‖2I (3)
where ‖f‖2I is the norm in the intrinsic space. The regularizer
parameters γA, γI control the smoothness of the solution
relative to the ambient and the intrinsic spaces, respectively.
It can be shown that when the intrinsic space is a compact
manifold M ∈ Rn then one natural choice for ‖f‖2I would be
‖f‖2I =
∫
M
‖∇Mf(x)‖2dPX (4)
where ∇M is the gradient of the function over the Riemannian
manifold M and it can be approximated with the graph
Laplacian corresponding to the proxy graph when the affinity
matrix takes the exponential form wij = e(−
‖xi−xj‖
 ) ∀i 6= j
and wii = 0 ∀i. This approximation reduces the intrinsic
penalty term to
‖f‖2I = fTLf (5)
where fT = [f(x1), . . . , f(xl+u)]. Finally, following from
the representer theorem [23], they showed that the solution to
equation 3 with the soft-margin loss function and equation 5
as the smoothness penalty term on the manifold (henceforth,
Laplacian support vector machine) takes the same form as in
equation 2 but with a different set of weights αi.
III. MATERIALS AND METHODS
A. Data
We used RNA-seq data corresponding to cancer tissues for
two cancer types, the kidney cancer (KIRC) and the neurob-
lastoma (NB) which occurs most often in infants and young
children. The data for the former cancer was retrieved from the
Cancer Genome Atlas (TCGA) data portal (http://www.tcga-
data.nci.nih.gov) and for the latter we used the data from
a previous published study [26]. These data were generated
using the Illumina HiSeq 2000 platform. In this study, we use
three different feature levels (gene, transcript and junction)
derived from these sequencing data. Table I shows the data
description for each modality and disease. We divided samples
into positive and negative classes according to a selected
patient survival threshold. For kidney cancer, this threshold
is 5 years and for neuroblastoma cancer it is 9 years. Table
II illustrates the statistics of each class and the percentage of
unlabeled samples. According to the table, more than half of
the samples from each dataset are unlabeled which justifies
the use of semi-supervised learning to benefit from them.
Fig. 1: Pipeline for Semi-Supervised Multi-Modal Prediction
Modeling
B. The proposed pipeline
Figure 1 depicts the block diagram of the proposed pipeline.
As illustrated in the figure, it includes four major steps,
namely, data pre-processing, feature selection, learning indi-
vidual SSL models, and finally consolidating these models to
produce a combined classifier.
In the first step, the genomic input data are parsed and stored
into feature matrices and survival times are retrieved from the
clinical records. Since we are dealing with a classification
task, the positive class includes those patients who lived
above some threshold of interest (e.g., 5 years for the kidney
cancer patients) or are still alive and their survival period as
of the last follow-up visit passed that threshold. Similarly,
the negative class comprises those samples who deceased
before the threshold. For future evaluations and training of the
pipeline, we randomly select a subset of the labeled samples
(15%) and split the rest to five folds to carry out five-fold
cross-validation according to a specified seed that we change
for repeated runs of the same experiments.
TABLE I: Data description
Cancer type Platform Modality #Features
NB
Illumina HiSeq 2000
Isoform 263547
Gene 60781
Junction 340417
KIRC
Isoform 73599
Gene 20531
Junction 249567
TABLE II: Number of labeled vs. unlabeled samples
Cancer type #Labeled Samples #Unlabeled Samples %Unlabeled#Positive #Negative
NB (9-y survival) 114 105 279 56%
KIRC (5-y survival) 110 140 278 53%
In the next step, to avoid overfitting, it is necessary to
perform a feature reduction step. We chose the minimum
redundancy maximum relevance (mRMR) [13] feature se-
lection technique which has been successfully applied in a
number of studies [13], [20], [21], [18] that deal with high
dimensional data from high-throughput experiments. mRMR
is an incremental search algorithm that looks for the sub-set
of features with highest relevance to the classes and lowest
redundancy. Both relevance and redundancy are defined in
terms of the mutual information. Specifically, relevance is
defined as the average mutual information between the selected
feature subset and the classes. Redundancy, on the other hand,
is defined as the average pairwise mutual information between
all the samples in the subset. Clearly in the ideal case where
all the selected features are independent, the pairwise mutual
information between any two features is zero and as a result,
the redundancy measure will be zero. Since, this is a multi-
objective optimization and there could be many non-dominated
solutions, a single objective function is defined as a weighted
sum of relevance and negative redundancy. As our goal here
is to select those features that are the key determinants of
the long-term vs the short-term survival, we computed the z-
score of each modality input matrix and discretized its entries
into three levels corresponding to those feature values that fall
within the ranges (−∞, 1.5σ], (−1.5σ, 1.5σ) and [1.5σ,∞).
Clearly, the set of differentially expressed genes (DEGs) are
expected to fall within the two extreme ranges, whereas those
genes which are uncorrelated to the clinical endpoint, are
assumed to exhibit smaller variability across the positive and
the negative classes. To find the optimal size of selected feature
sets as well as the pipeline hyper-parameters (e.g. ambient and
intrinsic space regularizers,γI and γA) we used the validation
set and conducted a grid search to pick the best configurations.
Once the number of features have been reduced, we train
multiple Laplacian SVM classifiers, one for each modality. We
used the library developed by the authors in [2] to train our
models. The heat (Gaussian) affinity kernel was selected to
generate the edge weights and Euclidean distance function to
compute the distance between the nodes. We used 5 nearest
neighbor method to filter out the links between distant nodes.
Moreover, we selected polynomial kernel of degree three (cf.
equation 2) which turns out to strike a good balance between
the generalizability and the expressivity of the individual
models. Lastly, to come up with a consolidated model, we
adopted the stacked generalization strategy [25] to weigh each
of the individual models according to their prediction scores.
This second layer model is trained over the prediction scores
produced by the single modality sub-models using a linear-
kernel support vector machine and thereby the prediction
scores from the previous layer are normalized so that no single
modality model dominates the role of other models just by
having a higher range of prediction scores.
IV. RESULTS
We used the proposed pipeline to predict survival of the
neuroblastoma (NB) and the kidney (KIRC) cancer patients.
In this section, we address two critical questions: (1) Does the
SSL approach improve prediction performance? And (2) How
does the overall pipeline perform relative to the individual data
models (denoted by Model #1, ..., #n in Figure 1)?
A. Supervised vs. semi-supervised strategies
We compared the performance of the Laplacian SVM
classifier (LapSVM) to its supervised counterpart, the support
vector machines (SVM). We evaluated the performance of
each model 100 times using different cross-validation training,
test, and, validation sets. Figure 2 depicts the box plot of
the resulting performance measures, for both the neuroblas-
toma and kidney datasets and the three RNA-seq modalities
mentioned above. Interestingly, for the NB dataset, the trained
models (both supervised and semi-supervised) can accurately
predict the 9-year survival with the semi-supervised models
doing significantly better (p = 0.0, 0.0, 0.0 for gene, junction,
and isoform, respectively). For the KIRC dataset, although the
LapSVM outperforms the supervised SVM on average, the
performance improvement is not statistically significant for the
junction and isoform modalities (p = 3.5e − 4, 0.2, 0.15 for
gene, junction, and isoform, respectively.) This is because of
the more heterogeneous nature of the kidney cancer and the
low predictivity of RNA-seq for this dataset, as evidenced by
the lower prediction accuracies compared to the neuroblastoma
dataset.
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Fig. 2: Comparison of SVM and LapSVM
To make the role of unlabeled data more tangible, in
another series of experiments, we trained the semi-supervised
LapSVM models with and without the unlabeled data. In other
words, we would like to uncover the impact of adding the unla-
beled data on the prediction accuracy. To this end, we repeated
the same set of experiments as in the previous subsection but
this time with an additional semi-supervised model that does
not leverage the unlabeled samples (LapSVM L). Figure 2
shows the resulting accuracies. According to the figure, adding
the unlabeled samples significantly improves the prediction
accuracy. In fact when unlabeled samples are not used, the
average performance falls below that of the supervised SVM
models.
B. Semi-supervised multi-modal pipeline vs. individual data
models
Finally, we investigated whether the semi-supervised multi-
modal pipeline performs at least as best as the individual
sub-models. Moreover, we computed similar results for the
supervised counterpart of the proposed pipeline, that is, when
the semi-supervised based single modality models are replaced
with the supervised SVMs. Table III illustrates the mean along
with the standard variation of the prediction accuracies across
100 randomly initialized settings both for the individual mod-
els and the pipelines. According to the Table a few key points
become evident. First, the semi-supervised models consistently
surpass the supervised ones and, second, by using a stacking
strategy the prediction accuracy increases synergistically (as is
the case for the KIRC dataset) or leads to performances that
closely follow the best sub-models (as is the case with the NB
dataset.)
According to the table the combined model predicts the sample
labels with higher or competitive accuracies compared to the
individual models.
V. DISCUSSION
Prediction of survival is a critical step in decision making
for patient’s therapy. A wrong estimate on patient’s survival
may lead to a choice which undermines the quality of life or
the success of the selected treatment. The current study aims
to help doctors to make more objective estimates based on the
genomic data recorded during the course of patient’s treatment.
In so doing, we developed a pipeline that predicts cancer
survival using multiple modalities of high-dimensional tran-
scriptomic data. We showed that by exploiting the manifold
structure of the cancer input sources and integrating multiple
modalities into a semi-supervised learning framework we can
achieve high accuracy. We showed that omics data alone can
explain a significant portion of the clinical outcome.
While we designed this pipeline for the task of cancer
survival prediction, its application is not limited to this area. In
fact, such a pipeline is applicable to other domains where there
are not enough labeled data available and plenty of unlabeled
data exist.
In this study, we only focused on transcriptomic data
modalities. However, a more comprehensive approach may
involve integration of different levels of genomic data. In
fact, cancer has been known to result from dysregulation by
multiple molecular mechanisms [7], [11] which can manifest
itself in changes in the DNA structure, copy number, DNA
methylation, histone modification, and miRNA regulation. As
a result, no single level of genomic data by itself can explain
the outcome independently. Therefore, it may be beneficial
to integrate the results of other high-throughput experiments
in different genomic levels to boost the prediction accuracy
which highlights the role of big-data analytics. The integration
of different layers of genomic data using SSL has been
explored in some of the recent published works such as [14],
[22]. Another direction that may be worth following is the
integration of both clinical and omics data. Clinical prognostic
factors convey valuable information that is not available in
omics data. Even if this information exists, we may not be
able to capture it or effectively process it in the pre-processing
and feature reduction phases. Finding an effective way to
combine these two inherently different sources of data may
be interesting future research.
TABLE III: Single modality vs integrated model: accuracy comparison
Cancer type Modality Mean ACC (±σ): Sup Mean ACC (±σ): Semi-Sup
NB
Isoform 82.25%(±2.60) 85.98% (±1.96)
Gene 83.04(±2.44)% 85.84% (±2.05)
Junction 84.50(±2.48)% 87.16% (±1.87)
Combined 84.93(±1.79)% 86.83% (±1.89)
KIRC
Isoform 63.52(±3.10)% 65.02% (±2.94)
Gene 61.68(±3.07)% 64.67% (±2.74)
Junction 62.65(±3.19)% 64.68% (±2.90)
Combined 66.07%(±2.54) 66.20% (±2.60)
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